About RemedyBio
RemedyBio is a company based in Dublin (Ireland) founded in 2017. RemedyBio has raised $9.43 million across 4 funding rounds from investors including Enterprise Ireland, European Union and Dublin City University. RemedyBio offers products and services including Therapeutic Discovery Platform and Immune System Mapping Tool. RemedyBio operates in a competitive market with competitors including Annexon, Syndax, Abingdon Health, Clovis Oncology and Spear Bio, among others.
- Headquarter Dublin, Ireland
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$9.43 M (USD)
in 4 rounds
-
Latest Funding Round
$22.91 K (USD), Grant
Jun 01, 2022
-
Investors
Enterprise Ireland
& 4 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of RemedyBio
RemedyBio offers a comprehensive portfolio of products and services, including Therapeutic Discovery Platform and Immune System Mapping Tool.
Platform for mapping cell functions to discover new immune therapies.
Tool that analyzes patient biology for therapeutic development.
Funding Insights of RemedyBio
RemedyBio has successfully raised a total of $9.43M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $22.91 thousand completed in June 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Grant — $22,914
-
First Round
First Round
(09 Jun 2020)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2022 | Amount | Grant - RemedyBio | Valuation |
investors |
|
| Jul, 2021 | Amount | Series A - RemedyBio | Valuation |
investors |
|
| Sep, 2020 | Amount | Grant - RemedyBio | Valuation |
investors |
Investors in RemedyBio
RemedyBio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Enterprise Ireland, European Union and Dublin City University.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Founded Year | Domain | Location | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Founded Year | Domain | Location | |
|
Support is provided to Irish manufacturing and service sector businesses.
|
Founded Year | Domain | Location |
Investments & Acquisitions by RemedyBio
Financial Statements - RemedyBio
Remedybio Comparisons
Competitors of RemedyBio
RemedyBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Annexon, Syndax, Abingdon Health, Clovis Oncology and Spear Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Targeted therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of immunoassays for diagnostic purposes
|
|
| domain | founded_year | HQ Location |
Develops innovative immunotherapy drugs for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Developer of ultrasensitive immunoassays and proteomics platforms for detecting protein biomarkers
|
|
| domain | founded_year | HQ Location |
Developer of cancer therapeutics for the treatment of blood cancer
|
Frequently Asked Questions about RemedyBio
RemedyBio was founded in 2017 and raised its 1st funding round 3 years after it was founded.
RemedyBio is headquartered in Dublin, Ireland.
RemedyBio is a funded company, having raised a total of $9.43M across 4 funding rounds to date. The company's 1st funding round was a Grant of $2.98M, raised on Jun 09, 2020.
RemedyBio was founded in 2017 in Dublin, Ireland, within the biotechnology sector. Personalized, cell-based, and autologous therapies targeting tumors are developed and offered. Nanoscale biotechnology is employed for diagnostic purposes in immunoncology, autoimmune diseases, and infectious conditions. Individual cell functions are analyzed across 10 million to 1 billion living cells to support therapeutic design and evaluation.
RemedyBio's top competitors include Syndax, Annexon and Abingdon Health.
RemedyBio offers Therapeutic Discovery Platform and Immune System Mapping Tool.
RemedyBio has 5 investors. Key investors include Enterprise Ireland, European Union, Dublin City University, Science Foundation Ireland, and EIC Fund.